Anti-GATA3 gene therapy - sterna biologicals

Drug Profile

Anti-GATA3 gene therapy - sterna biologicals

Alternative Names: hgd40; SB 010; SB 011; SB 012

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sterna biologicals; University of Marburg
  • Developer German Center for Lung Research; sterna biologicals
  • Class Anti-inflammatories; Antiasthmatics; Catalytic DNA; Gene therapies; Skin disorder therapies
  • Mechanism of Action GATA3 transcription factor inhibitors; Gene transference; Interleukin 13 expression inhibitors; Interleukin 4 expression inhibitors; Interleukin 5 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Ulcerative colitis

Most Recent Events

  • 11 Sep 2017 sterna biologicals completes a phase II trial for Chronic obstructive pulmonary disease in Germany (Inhalation) (DRKS00006087)
  • 22 Jun 2017 Sterna Biologicals completes a phase II trial in Ulcerative colitis in Germany (Rectal) (EudraCT2013-004599-36) (NCT02129439)
  • 07 Apr 2017 Efficacy data from a Sub-group analysis of phase IIa trial in Allergic asthma released by Sterna biologicals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top